Is Bruker Corp (BRKR) a risky stock?
As of July 27, 2026, Clavix grades Bruker Corp (BRKR) C- for risk, a composite score of 51 out of 100 on an A+ to F scale, which puts BRKR in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 27, 2026. Clavix regrades every trading day.
The five risk dimensions behind BRKR's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how BRKR scores on each, as of July 27, 2026.
What's moving BRKR's risk right now
Company-specific signals Clavix flags behind BRKR's current grade, drawn from recent news and filings as of July 27, 2026.
Bruker bought Noscendo's DISQVER platform, which uses whole-genome sequencing to detect pathogens directly from blood. The deal adds clinical metagenomics to Bruker's microbiology and infection diagnostics lineup.
Recent BRKR news
The latest headlines Clavix ingested for Bruker Corp, newest first. These feed the news-sentiment dimension of BRKR's grade.
What a C- grade means
On the Clavix A+ to F scale, BRKR's composite of 51 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell BRKR or any security. Grades are risk indicators, not predictions of return. Data may be delayed.